Cargando…
Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate
The limited efficacy of vaccines in hepatocellular carcinoma (HCC), due to the low frequency of tumor-infiltrating cytotoxic T lymphocytes (CTLs), indicates the importance of innate immune surveillance, which assists acquired immunity by directly recognizing and eliminating HCC. Innate Vγ9Vδ2 T cell...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809658/ https://www.ncbi.nlm.nih.gov/pubmed/26936487 http://dx.doi.org/10.3892/ijo.2016.3403 |
_version_ | 1782423677505110016 |
---|---|
author | SUGAI, SHIORI YOSHIKAWA, TOSHIAKI IWAMA, TATSUAKI TSUCHIYA, NOBUHIRO UEDA, NORIHIRO FUJINAMI, NORIHIRO SHIMOMURA, MANAMI ZHANG, RONG KANEKO, SHIN UEMURA, YASUSHI NAKATSURA, TETSUYA |
author_facet | SUGAI, SHIORI YOSHIKAWA, TOSHIAKI IWAMA, TATSUAKI TSUCHIYA, NOBUHIRO UEDA, NORIHIRO FUJINAMI, NORIHIRO SHIMOMURA, MANAMI ZHANG, RONG KANEKO, SHIN UEMURA, YASUSHI NAKATSURA, TETSUYA |
author_sort | SUGAI, SHIORI |
collection | PubMed |
description | The limited efficacy of vaccines in hepatocellular carcinoma (HCC), due to the low frequency of tumor-infiltrating cytotoxic T lymphocytes (CTLs), indicates the importance of innate immune surveillance, which assists acquired immunity by directly recognizing and eliminating HCC. Innate Vγ9Vδ2 T cells have major histocompatibility complex-unrestricted antitumor activity and are activated by phosphoantigens, which are upregulated in cancer cells by the nitrogen-containing bisphosphonate, zoledronate (Zol). A better understanding of HCC susceptibility to Zol and downstream γδ T cell-mediated killing is essential to optimize γδ T cell-mediated immunotherapy. This study systematically examined the interactions between γδ T cells and Zol-treated HCC cell lines (HepG2, HLE, HLF, HuH-1, JHH5, JHH7, and Li-7) in vitro. All HCC cell lines expressed the DNAX accessory molecule-1 ligands, poliovirus receptor, and Nectin-2, and γδ T cell-mediated killing of these cells was significantly enhanced by Zol. Small interfering RNA-mediated knockdown of these ligands did not affect the susceptibility to γδ T cell lysis. This killing activity was partly inhibited by mevastatin, an inhibitor of the mevalonate pathway, and markedly reduced by a monoclonal antibody to γ- and δ-chain T cell receptor, indicating that this is crucial for Zol-induced HCC killing. In addition, Zol-treated HCC cell lines triggered γδ T cell proliferation and induced production of Th1 and Th2, but not Th17, cytokines. The Zol concentration that enhanced HCC cell susceptibility to γδ T cell killing was lower than that required to directly inhibit HCC proliferation. Thus, γδ T cells may be important effector cells in the presence of Zol, especially where there are insufficient number of cancer antigen-specific CTLs to eliminate HCC. Our in vitro data support the proposal that Zol-treatment, combined with adaptive γδ T cell immunotherapy, may provide a feasible and effective approach for treatment of HCC. |
format | Online Article Text |
id | pubmed-4809658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-48096582016-04-06 Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate SUGAI, SHIORI YOSHIKAWA, TOSHIAKI IWAMA, TATSUAKI TSUCHIYA, NOBUHIRO UEDA, NORIHIRO FUJINAMI, NORIHIRO SHIMOMURA, MANAMI ZHANG, RONG KANEKO, SHIN UEMURA, YASUSHI NAKATSURA, TETSUYA Int J Oncol Articles The limited efficacy of vaccines in hepatocellular carcinoma (HCC), due to the low frequency of tumor-infiltrating cytotoxic T lymphocytes (CTLs), indicates the importance of innate immune surveillance, which assists acquired immunity by directly recognizing and eliminating HCC. Innate Vγ9Vδ2 T cells have major histocompatibility complex-unrestricted antitumor activity and are activated by phosphoantigens, which are upregulated in cancer cells by the nitrogen-containing bisphosphonate, zoledronate (Zol). A better understanding of HCC susceptibility to Zol and downstream γδ T cell-mediated killing is essential to optimize γδ T cell-mediated immunotherapy. This study systematically examined the interactions between γδ T cells and Zol-treated HCC cell lines (HepG2, HLE, HLF, HuH-1, JHH5, JHH7, and Li-7) in vitro. All HCC cell lines expressed the DNAX accessory molecule-1 ligands, poliovirus receptor, and Nectin-2, and γδ T cell-mediated killing of these cells was significantly enhanced by Zol. Small interfering RNA-mediated knockdown of these ligands did not affect the susceptibility to γδ T cell lysis. This killing activity was partly inhibited by mevastatin, an inhibitor of the mevalonate pathway, and markedly reduced by a monoclonal antibody to γ- and δ-chain T cell receptor, indicating that this is crucial for Zol-induced HCC killing. In addition, Zol-treated HCC cell lines triggered γδ T cell proliferation and induced production of Th1 and Th2, but not Th17, cytokines. The Zol concentration that enhanced HCC cell susceptibility to γδ T cell killing was lower than that required to directly inhibit HCC proliferation. Thus, γδ T cells may be important effector cells in the presence of Zol, especially where there are insufficient number of cancer antigen-specific CTLs to eliminate HCC. Our in vitro data support the proposal that Zol-treatment, combined with adaptive γδ T cell immunotherapy, may provide a feasible and effective approach for treatment of HCC. D.A. Spandidos 2016-02-19 /pmc/articles/PMC4809658/ /pubmed/26936487 http://dx.doi.org/10.3892/ijo.2016.3403 Text en Copyright: © Sugai et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles SUGAI, SHIORI YOSHIKAWA, TOSHIAKI IWAMA, TATSUAKI TSUCHIYA, NOBUHIRO UEDA, NORIHIRO FUJINAMI, NORIHIRO SHIMOMURA, MANAMI ZHANG, RONG KANEKO, SHIN UEMURA, YASUSHI NAKATSURA, TETSUYA Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate |
title | Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate |
title_full | Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate |
title_fullStr | Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate |
title_full_unstemmed | Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate |
title_short | Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate |
title_sort | hepatocellular carcinoma cell sensitivity to vγ9vδ2 t lymphocyte-mediated killing is increased by zoledronate |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809658/ https://www.ncbi.nlm.nih.gov/pubmed/26936487 http://dx.doi.org/10.3892/ijo.2016.3403 |
work_keys_str_mv | AT sugaishiori hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate AT yoshikawatoshiaki hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate AT iwamatatsuaki hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate AT tsuchiyanobuhiro hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate AT uedanorihiro hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate AT fujinaminorihiro hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate AT shimomuramanami hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate AT zhangrong hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate AT kanekoshin hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate AT uemurayasushi hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate AT nakatsuratetsuya hepatocellularcarcinomacellsensitivitytovg9vd2tlymphocytemediatedkillingisincreasedbyzoledronate |